Article: Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study.

EXTON, Pa., March 14 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. announced today the completion of enrollment of approximately 120 patients in its Phase II/III Study IT-A-008 investigating the Isolagen Therapy(TM) for the treatment of moderate to severe acne scars. Treatments, which will be administered at seven clinical sites across the U.S., have now commenced.

"We believe the Isolagen Therapy could hold great promise for the treatment of acne scars and are pleased to have completed this important clinical milestone as planned," said Declan Daly, Chief Executive Officer of Isolagen. "Concerning our pivotal clinical program on wrinkle correction, we expect to ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!